|
⚲
|
| Keyboard |
| Parkman Healthcare Partners LLC
✚
|
|
|---|---|
| CRD # | 300701 |
| SEC # | 801-114849 |
| CIK # | 0001777015 |
| AUM | 1,744.0 M (2026-03-27) |
| Employees | 12 (67% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-516-3690 |
| Address | 700 Canal Street Stamford, CT 06902 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| CIK | Period |
|---|---|
| 0001777015 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Stryker Corp | 50.9 | ||
| Dexcom Inc | 43.3 | ||
| Insulet Corp | 32.9 | ||
| Lilly Eli & Co | 31.8 | ||
| PTC Therapeutics Inc | 29.4 | ||
| Xenon Pharmaceuticals Inc | 28.9 | ||
| Boston Scientific Corp | 28.2 | ||
| CVS Caremark Corp | 27.8 | ||
| Arcus Biosciences Inc | 26.1 | ||
| Livanova PLC | 25.7 | ||
| Zimmer Holdings Inc | 24.4 | ||
| MBX Biosciences Inc | 23.9 | ||
| Biosante Pharmaceuticals Inc | 21.6 | ||
| Syndax Pharmaceuticals Inc | 21.1 | ||
| Qiagen NV | 20.0 | ||
| Envista Holdings Corp | 18.1 | ||
| Psivida Corp | 17.5 | ||
| AbbVie Inc | 16.3 | ||
| Biocryst Pharmaceuticals Inc | 16.3 | ||
| Quintiles Transnational Holdings Inc | 14.8 | ||
| Agios Pharmaceuticals Inc | 13.7 | ||
| Illumina Inc | 13.6 | ||
| Edwards Lifesciences Corp | 13.4 | ||
| Neurocrine Biosciences Inc | 13.1 | ||
| Kiniksa Pharmaceuticals Ltd | 12.5 | ||
| Ventrus Biosciences Inc | 11.4 | ||
| Structure Therapeutics Inc | 11.2 | ||
| McKesson Corp | 11.0 | ||
| Stoke Therapeutics Inc | 11.0 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Parkman Venture Partners SPV I LP | [2023-03-27] | 9.2 M | 4.1 M |
| Offered $9,250,000 · Filed 2022-05-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Parkman HP Master Fund LP | [2019-07-02] | 64.5 M | 718.9 M |
| Filed 2025-05-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 1,744.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 1,744.0 |
| By Discretionary | ||
| Discretionary | 7 | 1,744.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 1,744.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 1,744.0 | |
| United States Persons | 0.0 | |
| Total | 7 | 1,744.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Parkman Healthcare Partners LLC | Executive Officer | 3 | 2 | |
| Parkman Venture Partners GP LLC | Executive Officer | 1 | 1 | |
| Parkman HP Fund GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001777015] | |
| 3 | [0001777015] | |
| 4 | [0001777015] | |
| SC 13G | [0001777015] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Parkman Healthcare Partners LLC | InspireMD Inc | [2025-11-14] |
| Parkman Healthcare Partners LLC | Plus Therapeutics Inc | [2022-02-04] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300SDS6C71DAN3T72 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Martinez Gregory | |
| Parkman Healthcare Partners LLC | |
| Spruce Biosciences Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 232 | $19.33 | 4,485 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 25 | $17.46 | 436 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Buy | 256 | $17.91 | 4,585 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 232 | $19.33 | 4,485 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Buy | 256 | $17.91 | 4,585 |
|
Spruce Biosciences Inc SPRB
Common Stock, $0.001 par value per share
|
2025-10-06 | Sell | 25 | $17.46 | 436 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Tensile Capital Management LP
✚
|
CA | 1,796.0 M |
|
Morgan Creek Capital Management LLC
✚
|
NC | 1,790.2 M |
|
QVT Financial LP
✚
|
NY | 1,786.7 M |
|
Alta Park Capital LP
✚
|
CA | 1,779.6 M |
|
Great Point Partners LLC
✚
|
CT | 1,777.1 M |
|
OFS Capital Management LLC
✚
|
IL | 1,760.0 M |
|
RCF Management LLC
✚
|
CO | 1,757.0 M |
|
Long Path Partners LP
✚
|
CT | 1,732.8 M |
|
Galaxy Digital Capital Management LP
✚
|
NY | 1,723.0 M |
|
Wexford Capital LP
✚
|
FL | 1,720.5 M |